Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...
J.P. Morgan analyst Richard Vosser has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with Confidence: ...
Shares of Dover climbed after the company's 2025 earnings outlook beat expectations, and it posted a sharp rise in profit during the fourth quarter. The stock was trading 4.4% higher, at $206.04, in ...